HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Obeticholic Acid

HCID 447715
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
459789-99-2
Standard SMILES
CC[C@H]1[C@@H](O)[C@@H]2[C@H](CC[C@]3(C)[C@@H]([C@H](C)CCC(=O)O)CC[C@@H]23)[C@@]2(C)CC[C@@H](O)C[C@@H]12
InChIKey
ZXERDUOLZKYMJM-ZWECCWDJSA-N
Molecular formula
C26H44O4
Average molar mass
420.6 g/mol
Monoisotopic mass
420.32395988

Overview

Obeticholic acid is a dihydroxy-5beta-cholanic acid that is chenodeoxycholic acid carrying an additional ethyl substituent at the 6alpha-position. A semi-synthetic bile acid which acts as a farnesoid X receptor agonist and is used for treatment of primary biliary cholangitis. It has a role as a farnesoid X receptor agonist and a hepatoprotective agent. It is a dihydroxy-5beta-cholanic acid, a 3alpha-hydroxy steroid and a 7alpha-hydroxy steroid. It is functionally related to a chenodeoxycholic acid.

Names & identifiers

Preferred name
Obeticholic Acid
IUPAC
(4R)-4-[(3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
English name
Obeticholic Acid
Molecular formula
C26H44O4
Molecular weight
420.63

Names & synonyms

Obeticholic acid459789-99-26-ECDCAINT-7476-Ethylchenodeoxycholic acidOcaliva6-Ethyl-CDCAacido obeticolicoacide obeticholiqueDSP-1747INT747INT 747
Show more names
Obeticolic acid(R)-4-((3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid94701osv6alphC15636CS-1441
6alpha-ethylchenodeoxycholic acid6alpha-ethyl-3alpha,7alpha-dihydroxy-5beta-cholan-24-oic acid6-ethyl-3,7-dihydroxycholan-24-oic acidDSP17470462Z4S4OZCHEBI:43602DTXSID201966716-alpha-ethylchenodeoxycholic acid

Database identifiers

CAS
459789-99-2
PubChem CID
447715
DTXSID
DTXSID20196671
ChEMBL

Properties

Computed structural properties

XLogP
5.7
Topological polar surface area
77.8 Ų
Hydrogen bond donors
3
Hydrogen bond acceptors
4
Rotatable bonds
5
Heavy atoms
30
Formal charge
0
Complexity
649

Experimental & physicochemical properties

DrugsPharmaceuticals -> Listed in ZINC15
Human Drugs · 2 items

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Boiling Point562.9±25
Melting Point108-110
Dissociation Constants4.76±0.10

Physicochemical properties

Melting point
108 · 108-110 °C
Boiling point
562.9 · 562.9±25.0 °C(Predicted)
Density
1.091 · 1.091
storage temp.
-20 °C · -20°C
solubility
Soluble in DMSO (up to 35 mg/ml) or in Ethanol (up to 25 mg/ml)
form
White solid.
pka
4.76 · 4.76±0.10(Predicted)

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Warning

H315 (40%): Causes skin irritation [Warning Skin corrosion/irritation]

P203, P260, P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P318, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 5 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Hazard Classes and CategoriesSkin Irrit. 2 (40%)

Toxicology

Hepatotoxicity · 1 item

In multiple preregistration clinical trials, obeticholic acid was found to decrease serum enzyme elevations in a high proportion of patients with different liver diseases. Instances of paradoxical worsening of liver disease or further increases in serum ALT or AST were not reported. However, the product label for obeticholic acid includes warnings that serious liver related adverse events occurred more commonly with active therapy than with placebo treatment. In a pooled analysis of 3 placebo controlled trials in patients with primary biliary cholangitis, liver related adverse events were 5.2 per 100 patient exposure years with 10 mg and 2.4 with placebo. Even higher rates occurred with higher doses of obeticholic acid: 19.8 per 100 patient years for 25 mg daily and 54.5 for 50 mg daily. The clinical features, timing of onset, pattern of enzyme elevations and course of these events were not described in detail. Within a little over a year after approval of obeticholic acid as therapy for primary biliary cholangitis, the FDA published a warning letter stating that they had received notification of 19 deaths and 11 cases of severe liver injury in patients taking obeticholic acid, most but not all of whom had preexisting cirrhosis (Case 1). More recently, severe instances of hepatic decompensation have been reported in patients with both primary biliary cholangitis as well as primary sclerosing cholangitis, two similar chronic cholestatic liver diseases.

Chemistry & industry

Pharmacology

ATC Code · 3 items

A05AA04

A - Alimentary tract and metabolism

QA - Alimentary tract and metabolism

Protein BindingObeticholic acid and its metabolic conjugates are >99% plasma protein-bound.
Pharmacodynamics · 1 item

The activation of the FXR by obeticholic acid acts to reduce the synthesis of bile acids, inflammation, and the resulting hepatic fibrosis. This may increase the survival of patients with PBC, but to date, an association between obeticholic acid and survival in PBC has not been established.

Mechanism of Action · 1 item

Primary biliary cirrhosis is an autoimmune process by which the bile ducts and liver are damaged progressively, leading to fibrosis and cirrhosis. Bile acids increase the risk of damage and fibrosis to the damaged bile ducts. Obeticholic acid is a potent agonist of the farnesoid X receptor, which serves to regulate the hepatic metabolism of bile and cholesterol. This drug acts by binding to the farnesoid X receptor (FXR), found in the nucleus of liver and intestinal cells, which in turn increases liver bile flow, suppressing its production and decreasing hepatocyte exposure to excess levels of bile with cholestasis. Cholestasis is a process that normally causes inflammation and cirrhosis of the liver.

Biological Half-LifeThe biological half-life of obeticholic acid is reported to be 24 hours.
Metabolism/Metabolites · 1 item

The metabolism of obeticholic acid occurs in the liver. Obeticholic acid is conjugated with glycine or taurine, followed by secretion into bile. The conjugates are then absorbed in the small intestine and then re-enter the liver via enterohepatic circulation. The intestinal microbiota in the ileum converts conjugated obeticholic acid in a deconjugated form that may be either reabsorbed or eliminated. Glycine conjugates account for 13.8% of the metabolites and taurine conjugates account for 12.3%. Another metabolite, 3-glucuronide, may also be formed, but displays little pharmacological activity.

Related reactions

19 records
New reaction record
HRID 591866 reaction equation
HRID 591866As reactant
HRID 591867 reaction equation
HRID 591867As reactant
HRID 591868 reaction equation
HRID 591868As reactant
HRID 591869 reaction equation
HRID 591869As reactant
HRID 591870 reaction equation
HRID 591870As reactant
HRID 591871 reaction equation
HRID 591871As reactant
HRID 591872 reaction equation
HRID 591872As product
HRID 591874 reaction equation
HRID 591874As product
PreviousPage 1 of 3

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
CHEMBL566315
ChEBI
CHEBI:43602
UNII
0462Z4S4OZ
EC Number
810-245-2
Nikkaji
J2.007.345D
color
White
optical activity
4 to · [α]/D +4 to +6°, c =1.0 in methanol
Stability
2 years · Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 2 months.
InChIKey
ZXERDUOLZKYMJM-IMGBAYNYNA-N
SMILES
C[C@]12CC[C@@H](O)C[C@@]1([H])[C@@H](CC)[C@@H](O)[C@@]1([H])[C@]3([H])CC[C@]([H])([C@H](C)CCC(=O)O)[C@@]3(C)CC[C@]21[H] |&1:1,4,7,9,12,14,16,20,22,29,33,r|
FDA UNII
462 Z4S4OZ · 0462Z4S4OZ
NCI Drug Dictionary
obeticholic acid
ATC code
5 AA04 · A05AA04
Comptox DTXSID
20196671 · DTXSID20196671
UNSPSC Code
12352106 · 12352106
NACRES
77 · NA.77
Symbol(GHS)
7 · GHS07
Signal word
Warning
Hazard statements
315 · H315-H319-H335
Precautionary statements
261 · P261-P305+P351+P338
WGK Germany
3 · WGK 3
HS Code
2918199890 · 2918199890
Storage Class
11 · 11 - Combustible Solids
Adverse Effects · 1 item

The most common adverse effects associated with OCA administration include pruritus, fatigue, and abdominal pain and discomfort. Other reported adverse effects include rash, oropharyngeal pain, dizziness, constipation, arthralgia, dyslipidemia, headache, eczema, depression, hypersensitivity reactions, and abnormal thyroid function. The incidence of pruritus has been shown to increase in a dose-dependent manner and is increased when OCA is used as monotherapy. However, if a patient undergoes OCA therapy for 3 months without pruritus, this adverse effect is unlikely to occur subsequently.

Toxicity SummarySigns and Symptoms of Overdose
Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Obeticholic acid

vMost-DILI-concern

8

Box warning

DOI:10.1016/j.drudis.2016.02.015

Safety data

wgk
WGK 3
hs_code
2918199890
Signal word
Warning
Symbol(GHS)
GHS07
Storage Class
11 - Combustible Solids
Hazard statements
H315-H319-H335
Precautionary statements
P261-P305+P351+P338
FDA Pharmacological Classification · 5 items

0462Z4S4OZ

OBETICHOLIC ACID

Established Pharmacologic Class [EPC] - Farnesoid X Receptor Agonist

Mechanisms of Action [MoA] - Farnesoid X Receptor Agonists

Obeticholic acid is a Farnesoid X Receptor Agonist. The mechanism of action of obeticholic acid is as a Farnesoid X Receptor Agonist.

Absorption, Distribution and Excretion · 4 items

Obeticholic acid is absorbed in the gastrointestinal tract. The Cmax of obeticholic acid occurs at approximately 1.5 hours after an oral dose and ranges from 28.8-53.7 ng/mL at doses of 5-10mg. The median Tmax for both the conjugates of obeticholic acid is about 10 hours. One product monograph reports a Tmax of 4.5h for both 5 and 10mg doses. The AUC ranged from 236.6-568.1 ng/h/mL with 5mg to 10 mg doses.

About 87% of an orally administered dose is accounted for in the feces. Less than 3% of the dose can be recovered in the urine.

The volume of distribution of obeticholic acid is 618 L.

Clearance information for obeticholic acid is not readily available in the literature.

Applications · 3 items

DescriptionObeticholic acid is a semi-synthetic bile acid analogue and acts as a farnesoid-X receptor (FXR) agonist. It is used for the treatment of primary biliary cholangitis. It is also under investigation for the treatment of other liver diseases,primary biliary cirrhosis, bile acid diarrhea and related disorders. Study has shown that it also has potential for treating nonalcoholicsteatohepatitis (NASH), and portal hypertension. Obeticholic acid takes effect through acting s the agonist of the farnesoid X receptor (FXR), which is the regulator of bile and cholesterol metabolism in the liver.

DescriptionObeticholic acid is a potent and selective farnesoid X receptor agonist that promotes the flow of bile in the liver. The drug was approved by the USFDA for the treatment of the rare chronic liver disease primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with inadequate response to UDCA or as a single agent therapy in adults unable to tolerate UDCA. Obeticholic acid was discovered at the Università de Perugia and developed by Intercept Pharmaceuticals. Obeticholic acid has also been granted orphan drug designation for the treatment of primary sclerosing cholangitis and primary biliary cirrhosis and has received breakthrough therapy designation for the treatment of patients with nonalcohol steatohepatitis (NASH) with liver fibrosis.

Uses6-Ethylchenodeoxycholic Acid is a derivative of the bile acid Chenodeoxycholic Acid (C291900). 6-Ethylchenodeoxycholic Acid is a potent activator of the farnesoid X nuclear receptor which reduces liver fat and fibrosis in animal models of fatty liver disease.

Additional notes · 1 item

DefinitionChEBI: A dihydroxy-5beta-cholanic acid that is chenodeoxycholic acid carrying an additional ethyl substituent at the 6alpha-position. A semi-synthetic bile acid which acts as a farnesoid X receptor agonist and is used for treatme t of primary biliary cholangitis.